Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS. METHODS: -mutated PDAC. RESULTS: G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. CONCLUSIONS: -mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RMC-6236 is a RAS(ON) multi-selective inhibitor designed to target active GTP-bound RAS proteins across multiple KRAS mutant alleles.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [58]
Citations
Cites
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citation
Research works printed but not linked: 1
- Ying H, Kimmelman AC, Bardeesy N, Kalluri R, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2025;39:36-63.39510840
Cited by
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2605555 · Cited by 147
Self-citationAronchik, I., Kar, S., Zhuang, Y., Ahler, E., Lai, L., Seshadri, V., Yang, Y. C., Bulle, A. S., Ménard, M., Nayak, B., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04537-w · Cited by 32
“We previously reported the antitumor activity of daraxonrasib in this single-arm study in patients with metastatic PDAC receiving daraxonrasib as second-line treatment at 300 mg daily 12 ).”
InfluentialSelf-citationAdvances in RAS Therapeutics for Pancreatic Cancer
Der, C. J., & Yeh, J. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2600517 · Cited by 9
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
Arbour, K. C., Punekar, S. R., Luo, J., Johnson, M., Spira, A. I., Herzberg, B., Starodub, A., Sommerhalder, D., Hecht, J. R., Garrido‐Laguna, I., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2504059 · Cited by 9
Self-citationPLANET-MD: Ultra-fast Proteome-scale Prediction of Allosteric Networks in ProteinsPreprint
Sledzieski, S., & Hanson, S. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.12.659353 · Cited by 6
Nussinov, R., & Jang, H. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169985 · Cited by 5
Conroy, T., & Ducreux, M. P. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.08.003 · Cited by 3
Domain-alteration chimeras rewire oncogenic complexes in prostate cancer
Luo, J., Yang, J., Tien, J. C.-Y., Wang, M., Das, S., Wang, X., Young, E., Tošović, J., Mannan, R., Xiang, W., et al. (2026) · Nature · doi:10.64898/2026.04.24.720638 · Cited by 3
Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer
Killock, D. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01162-x · Cited by 2
KRAS inhibition is an effective therapy for appendiceal adenocarcinoma
Chowdhury, S., Ito, I., Pattalachinti, V. K., Yousef, A. M. G., Yousef, M., Khoury, S. E., Hornstein, N. J., Seldomridge, A. N., Hong, D. S., Overman, M. J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01817-3 · Cited by 3
“In particular the recent Phase 1/2 study of pan-KRAS inhibitor RMC-6236 had 30% of patients experience a grade 3 or greater toxicity with rash, diarrhea, and nausea being most common [46].”
Self-citationRobb, R. N., Ackermann, S. E., Degan, S. E., Taylor, K. E., Yang, R. Y., Marler, A. Z., Calvert, V. S., Pierobon, M., Lyons, S. P., Barker, N. K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0731 · Cited by 2
“Daraxonrasib (RMC6236) has demonstrated clinical activity in previously treated advanced RAS-mutated pancreatic cancer (16) and is now being evaluated across PDAC disease settings, including first-line metastatic ( Continued on the following page .)”
Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond
Schürmann, H., Park, W., O'Kane, G. M., Sciortino, C., Niger, M., Reichert, M., Olive, K. P., Pretzell, I., & Westphalen, C. B. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01236-x · Cited by 3
“…consisting of clinically manageable gastrointestinal (e.g., nausea, vomiting, diarrhea) and dermatologic (rash, stomatitis, onycholysis) toxicities [99]. a 1L: first-line therapy; ≥ 2L: at least one line of prior therapy; mixed: multiple indications/experimental arms that cannot be assigned to one…”
Self-citationHu, L., Ahmari, N., Schaeper, A., Pundavela, J., Kim, M., Dombi, E., Wu, J., Brunmair, J., Petronczki, Ö. Y., & Ratner, N. (2026) · Science Advances · doi:10.1126/sciadv.aeg3475 · Cited by 2
“…daraxonra-sib (RMC-6236), have shown a toxicity profile dominated by rash and gastrointestinal effects without prominent ocular or cardiac signals ( 37 ), suggesting that RAS-targeted approaches may be better tolerated in patients who cannot continue MEK inhibition due to these specific toxicities.”
Ai, X., Song, Z., Wu, L., Zhou, A., Cheng, D., Zong, H., Wu, H., Niu, Z., Sun, Y., Zhu, L., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04559-4 · Cited by 3
“In the RMC-6236-001 study, the median PFS and median OS was 4.3 months and 8.6 months in 3L and above for patients with PDAC harboring RAS-G12X mutation, which was shorter than that in the 2L setting (that is, 8.5 months of median PFS and 13.1 months of median OS) 30 .”
InfluentialShi, S., Wei, M., Du, N., Li, J., Han, B., Wang, W., Hu, X., Luo, F., Xu, J., & Yu, X. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.08.012 · Cited by 2
Daraxonrasib in Advanced RAS -Mutated Pancreatic Cancer
Sun, X., Chen, B., & Wang, S. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2607459 · Cited by 2
Wang, Y., Zhang, Y., Wang, X., Zhao, W., Li, Q., Zhou, M., Liu, Y., Yi, X., He, J. I., Li, Y. P., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02712-8 · Cited by 2
“Furthermore, Darax-onrasib demonstrated good tolerability and manageable safety, and no new safety signals were observed [296].”
Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma
Zacharia, G. S., Pandey, U., Thartori, O., Veena, F., Acharya, S., Shah, L. K., Patel, R., & Patel, H. (2026) · Cureus · doi:10.7759/cureus.113927 · Cited by 2
“The phase I/II trial by Wolpin et al. reported a Tmax of 1.6 to 3.9 hours [14].”
InfluentialZhang, Y., Sun, Z., Ding, H., Zou, C., Dong, L., Xu, Q., Ji, J., Han, X., Yu, H., Xu, D., et al. (2026) · MedComm · doi:10.1002/mco2.70903 · Cited by 1
“Daraxonrasib (RMC-6236), an oral RAS(ON) multi-selective inhibitor, recently demonstrated substantial anti-tumor activity in patients with previously treated metastatic PDAC harboring RAS mutations, leading to U.S. Food and Drug Administration Breakthrough Therapy Designation in 2025 [ 28 ].”
Pillozzi, S., Giommoni, E., Petroni, G., Rossini, D., Lavacchi, D., Brugia, M., Galli, A., & Antonuzzo, L. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01834-2 · Cited by 1
KRAS-driven cytokine–metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma
Huang, C., Mai, G., Li, Y., Liu, H., & Huang, W. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1899014 · Cited by 1
“Clinically, daraxonrasib (RMC-6236) showed activity in previously treated RAS-mutated PDAC in a phase 1/2 study and improved overall and progression-free survival versus chemotherapy in the phase 3 RASolute 302 trial (O’Reilly et al., 2026; Wolpin et al., 2026).”
Gong, J., Muranaka, H., Choi, S. Y., Tighiouart, M., Bhute, S., Aja, E., Jacobs, J. P., Stotland, A. B., Eyk, J. E. V., Elmadbouh, O. H. M., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01225-z · Cited by 1
“Additionally, the landscape for advanced PDAC is rapidly evolving with the advent of RAS inhibitors 20 .”
KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
Cai, J., Wu, Y., Jia, X., Yang, L., Yang, W., Lu, W., Huang, Z., Pan, Y., Fei, Z., Ru, J., et al. (2026) · MedComm · doi:10.1002/mco2.71050 · Cited by 1
Breaking the RAS Barrier in Pancreatic Cancer
Sivakumar, S. (2026) · New England Journal of Medicine · doi:10.1056/nejme2606948 · Cited by 1
Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven CancerPreprint
Thege, F. I., Kramer, A., Kreisz, N., Salim, I., Girma, E. G., Welte, L., Adams, E., Pluchinsky, A., Kirschstein, E., Harder, O. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.02.742234 · Cited by 1
Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence
Ranganathan, S., & Olivier, T. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01457 · Cited by 1
Kano, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135796
“Among emerging pan-RAS therapeutics, RMC-6236 has become one of the most prominent and clinically advanced agents [58].”
Piejko, M., Bak, K., Wierciak, J., Plutecka, H., Wilczyńska-Zawal, N., Osmola, M., Rapacz, K., Kijowski, J., Mensah‐Glanowska, P., Szczepanik, A., et al. (2026) · Cancers · doi:10.3390/cancers18111852
“…a Phase I/II trial evaluating the RAS(ON) multi-selective inhibitor daraxonrasib demonstrated encouraging clinical activity, yielding a median PFS of 8.5 months and a median OS of 13.1 months in previously treated patients with metastatic PDAC, albeit with a non-negligible toxicity profile [45].”
InfluentialM1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLSPreprint
Takamori, S., Haratake, N., Nonaka, K., Moriya, M., Bhattacharya, A., Takenaka, T., Yoshizumi, T., Long, M. D., & Kufe, D. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.20.733526
“Daraxonrasib has substantial activity in patients with previously treated metastatic PDAC RAS mutant cancers 3, 4 .”
Kaya, D. M., Ma, Y., Demir, T., Altomare, N., Kalyan, A., Kircher, S. M., Mulcahy, M. F., Benson, A. B., Chen, R., & Mahalingam, D. (2026) · Cancers · doi:10.3390/cancers18132037
“Until recently, KRAS was widely considered an undruggable target, further limiting therapeutic exploitation of these molecular distinctions [19–21].”
Valencia-Sama, I., Kee, L., Weiss, A., Hayes, M. N., Ohh, M., & Irwin, M. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.24.734371
Therapeutic inhibition of RAS in non-small cell lung cancer
Nichols, K. B., & Herzberg, B. O. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1817943
“Intriguingly, serum pharmacokinetics shows higher median concentrations in NSCLC patients; it is also possible that PDAC has intrinsically higher therapeutic resistance compared to NSCLC. Based on these results (141), daraxonrasib There are several unique clinical features of daraxonrasib.”
Self-citationGesamtüberleben verlängert – aber um wie lang?
Borchers, M., & Klein, F. (2026) · Gastro-News · doi:10.1007/s15036-026-4067-2
Hsiao, Y.-C., Bai, L., Chen, Y.-J., Wu, Y., Wang, W., Chuang, Y.-L., Chang, H., Zeshan, M., Wu, H., Yang, H.-J., et al. (2026) · medRxiv · doi:10.64898/2026.07.01.26356985
Issa, A. M. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.70079
Abdelsamia, M., Li, Y., Eastwood, D., & Rabinowitz, I. (2026) · Future Oncology · doi:10.1080/14796694.2026.2699426
“…>90% of PDAC—demonstrated an ORR of 35%, median progression-free survival (PFS) of 8.5 months, and median OS of 13.1 months in second-line RAS G12-mutant PDAC in a Phase I/II study, markedly exceeding historical benchmarks of ~2–3 months PFS and ~5–7 months OS with second-line chemotherapy [18].”
InfluentialChen, J. Y., Saghapour, E., Kurmachalam, N., Oishe, G., & Sembay, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.09.737590
Parent, B. D., Kelly, A. E., Hoffman, M. T., Dougan, M. L., Aguirre, A. J., & Dougan, S. K. (2025) · Immunotherapy Advances · doi:10.1093/immadv/ltag013
“Finally, KRAS inhibition with daraxonrasib or other agents are showing impressive clinical responses and may have immune-potentiating side effects from limiting KRAS-driven production of immunosuppressive cytokines [25–27].”
Tai, J., He, H. Z., Perini, M. V., & Nikfarjam, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146290
“However, clinical responses to KRAS G12C inhibitors in PDA remain modest, and resistance to RAS-directed agents frequently emerges through feedback reactivation of parallel signaling nodes [17,18].”
Palliative Systemic Therapy in Advanced Thymic Epithelial Tumors in 2026—A Narrative Review
Saalfeld, F. C., & Overbeck, T. R. (2026) · Cancers · doi:10.3390/cancers18142354
“As panRAS inhibitors move to the clinic, this might become relevant for some patients in the near future [91].”
Masetti, M., & Lorenzen, S. (2026) · Trillium Krebsmedizin · doi:10.47184/tk.2026.04.3
Guzauskas, G., Picozzi, V., Guzman, J. F. N. D. R., & Wang, B. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2707046
Daraxonrasib and Beyond: Pan‐ RAS Inhibition, Resistance, and Next‐Generation Strategies
Honda, R. P. (2026) · Cancer Science · doi:10.1111/cas.70497
Hruban, R. H., & Kern, S. E. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101059
Jaffee, E. M., & Yap, T. A. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-01367
Fu, Y., Amiot, M., Kuzniak, I., Jouenne, F., Mourah, S., Lebbé, C., & Dumaz, N. (2026) · Oncogene · doi:10.1038/s41388-026-03951-1
Kang, S., Parikh, M., Pappas, L., Bi, L., Koenig, J. L., Yeap, B. Y., Carzo, N., Grillo, T. M., Baiev, I., Asupoto, O., et al. (2026) · medRxiv · doi:10.64898/2026.08.06.26359422
“The advent of RAS inhibitors as monotherapy and in combination with chemotherapy now presents an important additional treatment option 3 .”
Self-citationFrom RAS inhibitor resistance to rational combination strategies
Lynch, P., Macarulla, T. M., & O'Kane, G. M. (2026) · Nature Medicine · doi:10.1038/s41591-026-04529-w
Haldar, S. D., Wetzel, M., Lu, J., Lee, J. W., Sinan, H., Jakubowski, C. D., Saj, F., Pavlick, D. C., Graf, R. P., Quintanilha, J. C. F., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2699
Self-citationTherapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
Facchinetti, F., Friboulet, L., Liao, L., Peroni, M., Nakazawa, S., Zullo, L., Aldea, M., Pecci, F., Makarem, M., Alonso-García, I., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.08.004
Single-Cell Mapping of Malignant Signaling Networks Guides Drug CombinationsPreprint
Yavuz, B. R., Jang, H., & Nussinov, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.12.744506
Tumor-tropic E. coli engineered as living T and NK cell engagersPreprint
Yang, S., Bader, A. C., Sendker, S., Hu, A., Chen, D. C., Nath, H., Chen, A., Bobilev, E., Sheffer, M., Hui, V. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.18.745642
Cholangiozelluläres Karzinom als Modellerkrankung: Neue Wege in der personalisierten Medizin
Barsch, M., & Bengsch, B. (2026) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2615-7493
Meng, D., & Zhang, C. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1948028
“In the phase I/II RMC-6236–001 study (NCT05379985), second-line daraxonrasib 300 mg produced a 35% objective response rate, median progression-free survival of 8.5 months, and median overall survival of 13.1 months in RAS G12-mutant PDAC (Wolpin et al., 2026).”
InfluentialKRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target
Iftikhar, S., Xiao, A. H., Jin, Z., & Aly, E. H. (2026) · Current Oncology · doi:10.3390/curroncol33090514
“These inhibitors have a wider scope of mutational targets, and can even extend to specific variants [84].”
RASolute 302: lessons learned and the road ahead in pancreatic cancer
Ko, A. H. (2026) · The Oncologist · doi:10.1093/oncolo/oyag346
Equipoise lost in pancreatic cancer: reimagining crossover for promising cancer therapies
Vora, K. B., & Bates, S. E. (2026) · The Oncologist · doi:10.1093/oncolo/oyag347
Khan, H. Y., Hallak, M. N. A., Aboukameel, A., Bannoura, S. F., Uddin, M. H., Aboukameel, A., Alkan, F. K., Çağlayan, A. B., Alkan, H. K., Bao, B., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218804
Radoš, L., Čubranić, S. M. M., Golčić, M., Skočilić, I., Mikolašević, I., & Belančić, A. (2026) · Pharmaceuticals · doi:10.3390/ph19091371
“Encouraging phase I/II results in previously treated RAS-mutated pancreatic adenocarcinoma demonstrated a median OS of 14.5 months, establishing the rationale for phase III evaluation [32].”
InfluentialFrom “undruggable” to controllable: Milestones in pancreatic cancer therapy
Qi, H., Zhang, S., & Liu, M. (2026) · The Innovation Medicine · doi:10.59717/j.xinn-med.2027.100273
Chemically Induced Proximity in Biological Modulation
Jin, X., Zhou, C., & Zhang, X. (2026) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.6c00121
Akl, M. M., Ali, A. A. M., Hamad, K. S. S., & Ahmed, A. K. K. (2026) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.47510
Tsokkou, S., Papakonstantinou, M., Chatzikomnitsa, P., Gkaitatzi, A. D., Toutziari, E., Giakoustidis, D. E., Papadopoulos, V. N., & Giakoustidis, A. E. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17030048
The Times They Are A-Changin’: Pancreatic Cancer Surgery in the RAS Inhibitor Era
Tiriac, H., & Lowy, A. M. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20525-3
Li, L., Li, J., Yang, L., Zhou, J., & Ma, Y. (2026) · Pharmaceuticals · doi:10.3390/ph19091388
“Clinically observed toxicities, particularly rash, gastrointestinal events, and stomatitis or mucositis, highlight the need for careful dose optimization, especially as these agents move into earlier-line and combination settings [41].”
Resistance to third-generation EGFR TKIs - what can be expected from the fourth-generation?
Dempke, W. C. M., Fenchel, K., Sullivan, L., & Reck, M. (2026) · Cancer Drug Resistance · doi:10.20517/cdr.2026.79
DaSilva, B. A., Neugut, A. I., Fojo, T., & Bates, S. E. (2026) · The Oncologist · doi:10.1093/oncolo/oyag354
Kage, M., Kawada, H., Takano, K., Matsuo, A., Murata, Y., Hashimoto, S., Tamiya, M., Kotake, T., Kuramoto, S., Yamano, T., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c14212
Drugging the “undruggable” p53: a structure-guided strategy against the Y220C mutation
Song, L., & Wang, H. (2026) · Medical Review · doi:10.1515/mr-2026-0050
“…noncovalent inhibitor RMC-6236, which targets the active state of RAS, covers multiple mutations including G12D, G12V, and G12C, and has demonstrated objective responses in clinical trials, suggesting that a broad-spectrum noncovalent strategy holds greater clinical applicability [9].”
Wang, E., Yao, A., Sasaki, M., Tanaka, R., Hassanein, M., Fujiwara, Y., & Tokuhara, T. (2026) · Journal of Clinical Question · doi:10.69854/jcq.2026.0026
The Landmark Series: Mutation-Based Therapy of Pancreatic Cancer
Schaefer, M. L., Tsai, S., & Blair, A. B. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20366-0
Lanthier, L., Pool, G., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.08.016
The dawn of RAS-targeted therapy: a landmark breakthrough of daraxonrasib in pancreatic cancer
Liu, C., & Liu, L. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00072-4
“Given the long‑standing therapeutic stagnation in this field, the simultaneous publication of two daraxonrasib studies in N Engl J Med marks a historic turning point [6, 7].”
Advances in KRAS-Targeted Therapies for Pancreatic Cancer
Peshin, S., Zahid, A., Takrori, E., Hamedi, Z., & Rahman, S. (2026) · Cancers · doi:10.3390/cancers18182961
“…in early-phase studies and the significant overall survival https://doi.org/10.3390/cancers18182961 and progression-free-survival benefits demonstrated in the phase III RASolute 302 trial indicate that clinically meaningful broad RAS inhibition can be achieved within a therapeutic window [34,35].”
InfluentialThe Role of KRAS in Non-Small Cell Lung Cancer: From Molecular Background to Precision Medicine
Gaździcka, J., & Gołąbek, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188194
“…and multi-selective RAS-directed approaches, selecting combinations according to co-mutations and adaptive signalling, integrating ctDNA for longitudinal molecular monitoring [11], and determining where KRAS-directed vaccines or TCR strategies can add clinically meaningful benefit [127,134,136–140”
Chen, S., Xie, Y., Xu, S., Su, L., Xu, Y., Liu, S., Zheng, Q., Liu, Q., & Sun, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1908017
“…nearly doubled median overall survival to 13.2 months compared with 6.7 months for standard chemotherapy in previously treated metastatic PDAC (17, 18) — these data underscore that even highly effective targeted monotherapies achieve only modest absolute survival bene fi ts (Compared with the…”
InfluentialNeoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancerPreprint
Hilmi, M., Schoenfeld, J. D., McKerrow, W., Elhanati, Y., O’Connor, C. A., Umeda, S., Lecomte, N., Melchor, J. P., Cardenas, A., Lao, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.17.752426
Self-citationAceituno, L., Valenzi, E., Segatto, O., Saborowski, A. L., & Vogel, A. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.102619
Li, Y., Zhang, Z., Li, D., Zhou, C., Chen, Y., Zhu, C., Yang, J., Tang, R., Wang, W., Yu, X., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.103044
“Although targeted therapies including PARP inhibitors [7] and KRAS inhibitors [8] have exhibited encouraging preliminary efficacy, they have not yet been incorporated into routine clinical practice.”
Chiang, C., Chan, S.-K., Lee, A. S. F., Lam, K. M. E., Wong, C. Y. E., Chan, C. W. D., Chan, K. K., Li, S., Wong, J. W. H., Chiu, K. W.-H., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00323
Debien, V., Cremieux, A. G., Grand, M. L., Carbone, D., Garajová, I., Pecoraro, C., Pasquier, E., Peters, G. J., Giovannetti, E., Centanni, M., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108576
“38,39 Another example includes TP53 -mutated tumors, for which controversial roles in drug resistance have been reported, usually depending on the drug.”
Gierulska, N., Jankowska, N., Dąbrowska, Z., Piekarz, J., & Skórzewska, M. (2026) · Cancers · doi:10.3390/cancers18193112
“The probability of remaining progression-free at 6 and 9 months was 78% and 46%, respectively, and the probability of survival at 9 months was 89% [19].”
InfluentialMuhammad, M., Khinji, A. A., Al-Ansari, M., Al-Marri, N., Al-Shaheen, S., & Malouche, D. (2026) · Cancers · doi:10.3390/cancers18193139
“Two of them were the daraxonrasib trials [51,52]: these were excluded from the synthesis because daraxonrasib is a multi-selective RAS(ON) inhibitor active across RAS G12 variants rather than an allele-selective agent, so it cannot contribute to an allele-stratified comparison, and because pooling…”
InfluentialLou, J., & Zhang, D. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00833-w · Cited by 2
“The safety profile in this study was characterized by treatment-related adverse events (TRAEs) of any grade in 96% of patients, with grade 3 or higher events in 30% [17].”
InfluentialHarnessing novel agents to target KRAS-driven pathways in pancreatic cancer
Kreidi, J., Hoyek, C., Eslinger, C. R., & Bekaii-Saab, T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2738708
“These effects were generally manageable with prophylactic antibiotics, emollients, and sunscreen, with dose modification for grade 3 events [94].”
DeLiberty, J. M., Kong, F. Y., Yu, Q., Sindoni, N., Lin, J., Kang, K., Kim, E. Y., Chen, S., Padhye, A., Coker, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756025
Rajadurai, C. V., Harrigan, D., Lafleur, J., Labidi, S., Panet, F., Elkholi, I. E., Papadakis, A. I., Mamo, A., Aguilar, A., Susie, L., et al. (2026) · medRxiv · doi:10.64898/2026.10.01.26364445
A (Post)translational Opportunity in RAS-Dependent Heme Malignancy
Boise, L. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0319
Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma
Yamazaki, S., Hondo, N., Yasukawa, K., Kitazawa, M., Nakamura, S., Yamamoto, Y., Miyazaki, S., Tanaka, H., Kuroiwa, M., Ishizaka, N., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00835-8
“Based on these encouraging findings, randomized phase III studies evaluating darax-onrasib support the translational relevance of pan-RAS (ON) inhibition and provide a strong rationale for exploring daraxonrasib-based combination approaches in other KRAS-driven malignancies [28, 29], including CCA.”
Coriat, R. (2026) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2026.100849
Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More
Yu, P. Y., Oberstein, P. E., Maitra, A., & Hidalgo, M. M. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4177 · Cited by 1
Targeting RAS in pancreatic cancer
Petrelli, F., Dottorini, L., & Zaniboni, A. (2026) · Cancer · doi:10.1002/cncr.70640 · Cited by 1
Sinan, H., Sleiman, E. A., Blackford, A. L., Shinozuka, T., Melki, D., Saab, J., Romanos, M., Ning, K., Almardini, M., Castellino, A., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.10.013
Beyond target presence: A cross-cancer contextual framework for siRNA therapeutics in solid tumors
Zhao, N., Zhang, Y., Qian, C., 张华巍, & Wang, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189732
Blockade of mutant RAS oncogenic signaling: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.109669
Cholangiozelluläres Karzinom als Modellerkrankung: Neue Wege in der personalisierten Medizin
Barsch, M., & Bengsch, B. (2026) · TumorDiagnostik & Therapie · doi:10.1055/a-2954-8120
Early-Phase Drug Development in Rare Cancers: A Decade of Progress and Future Directions
Myat, Y. M., Thein, K. Z., Mahmood, L., Ma, W. W., Eng, C., & Shanshal, M. (2026) · Cancers · doi:10.3390/cancers18203290
Zhang, S., 郝少龙, Dong, X., Deng, Q., Liu, J., Wen, T., & Han, W. (2026) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2026.10.001
王海英, Chen, H., Li, S., & Zhao, J. (2026) · Cancer Innovation · doi:10.1002/cai2.70082
Metadata
- Authors
- Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., Azad, N. S., Hecht, J. R., Ou, S. H. I., Lin, T., Kar, S., Tao, L., Vora, R., Hegde, A., Aung, K., & Hong, D. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- NEXT Oncology Virgina, Virgina Cancer Specialists Research Institute, Fairfax
- Christ Hospital (US)
- NEXT Oncology, San Antonio, TX
- NYU Langone Health (US)
- Mary Crowley Cancer Research Center (US)
- Sarah Cannon Research Institute, Nashville
- Columbia University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of California, Los Angeles (US)
- University of California, Irvine (US)
- Revolution Medicines (United States) (US)
- Miami Cancer Institute, Miami
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-05-07
- Volume
- 394
- Issue
- 18
- Pages
- 1790-1802
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W7160408317
- Cited by
- 90
- References
- 35
- Citations by year
- 2026: 89
- FWCI
- 263.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Revolution Medicines
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- daraxonrasib, RMC-6236, objective response rate, progression-free survival, overall survival
- MeSH terms
- Progression-Free Survival, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Pancreatic Neoplasms, Piperazines, Genes, ras, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.